BMS-354825
Jump to navigation
Jump to search
Indications
Mechanism of action
- inhibits bcl-abl that stimulates proliferation of abnormal leukocytes
- binds to different site than imatinib
- effective in 14 of 15 imatinab-resistant tumors
More general terms
References
- ↑ Journal Watch 24(18):124, 2004 Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004 Jul 16;305(5682):399-401. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15256671